533640 GPR119 Agonist II, GSK1292263 - CAS 1032823-75-8 - Calbiochem

533640
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service
      View Pricing & Availability

      Overview

      Replacement Information

      Key Specifications Table

      Empirical FormulaCAS #
      C₂₃H₂₈N₄O₄S 1032823-75-8

      Pricing & Availability

      Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
      5.33640.0001
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service
          Contact Customer Service

          Glass bottle 10 mg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewAn orally bioavailable, non-toxic oxadiazolyl-piperidinylpyridine compound that acts as a potent, selective and reversible agonist of GPR119 (pEC50 ~ 6.8 for hGPR119 & rat GPR119) with no significant in vitro off-target effects in 102 assays (in the range of 1 - 10 µM) and against CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2 (IC50 > 30 µM). Stimulates glucose-dependent/sensitive insulin secretion (pEC50 = 8.5 in GLUTag cells), improves glucose tolerance, elevates circulating GIP (glucose-dependent insulinotropic peptide) & GLP-1 (glucagon like peptide-1) levels and reduces body weight and food intake in rats. Also functions as a lipid modifying agent by increasing fasting plasma high density lipoprotein cholesterol (HDLc) and reducing fasting LDLc, as well as fasting and prandial triglycerides.

          Please note that the molecular weight for this compound is batch-specific due to variable water content. Please refer to the vial label or the certificate of analysis for the batch-specific molecular weight. The molecular weight provided represents the baseline molecular weight without water.
          Catalogue Number533640
          Brand Family Calbiochem®
          Synonyms5-(((1-(3-(1-Methylethyl)-1,2,4-oxadiazol-5-yl)-4-piperidinyl)methyl)oxy]-2-(4-(methylsulfonyl)phenyl)pyridine, GSK-1292263
          References
          ReferencesNunez, D.J., et al. 2014. PLoS ONE. 9, e92494.
          Polli, J.W., et al. 2013. Xenobiotica. 43, 498.
          Product Information
          CAS number1032823-75-8
          FormWhite solid
          Hill FormulaC₂₃H₂₈N₄O₄S
          Chemical formulaC₂₃H₂₈N₄O₄S
          ReversibleY
          Applications
          Biological Information
          Primary TargetGPR119
          Purity≥98% by HPLC
          Physicochemical Information
          Cell permeableY
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Ambient Temperature Only
          Toxicity Standard Handling
          Storage +2°C to +8°C
          Protect from Light Protect from light
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          GPR119 Agonist II, GSK1292263 - CAS 1032823-75-8 - Calbiochem SDS

          Title

          Safety Data Sheet (SDS) 

          References

          Reference overview
          Nunez, D.J., et al. 2014. PLoS ONE. 9, e92494.
          Polli, J.W., et al. 2013. Xenobiotica. 43, 498.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision20-November-2015 JSW
          Synonyms5-(((1-(3-(1-Methylethyl)-1,2,4-oxadiazol-5-yl)-4-piperidinyl)methyl)oxy]-2-(4-(methylsulfonyl)phenyl)pyridine, GSK-1292263
          DescriptionAn orally bioavailable, non-toxic oxadiazolyl-piperidinylpyridine compound that acts as a potent, selective and reversible agonist of GPR119 (pEC50 ~ 6.8 for hGPR119 & rat GPR119) with no significant in vitro off-target effects in 102 assays (in the range of 1 - 10 µM) and against CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2 (IC50 > 30 µM). Stimulates glucose-dependent/sensitive insulin secretion (pEC50 = 8.5 in GLUTag cells), improves glucose tolerance, elevates circulating GIP (glucose-dependent insulinotropic peptide) & GLP-1 (glucagon like peptide-1) levels and reduces body weight and food intake in rats. Also functions as a lipid modifying agent by increasing fasting plasma high density lipoprotein cholesterol (HDLc) and reducing fasting LDLc, as well as fasting and prandial triglycerides.
          FormWhite solid
          Intert gas (Yes/No) Packaged under inert gas
          CAS number1032823-75-8
          Chemical formulaC₂₃H₂₈N₄O₄S
          Purity≥98% by HPLC
          SolubilityDMSO (50 mg/ml)
          Storage +2°C to +8°C
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Toxicity Standard Handling
          ReferencesNunez, D.J., et al. 2014. PLoS ONE. 9, e92494.
          Polli, J.W., et al. 2013. Xenobiotica. 43, 498.